Senna Bio completed the C+ round of financing of over 200 million yuan

Senna Bio is a high-tech enterprise engaged in the research and development of gene sequencing technology. The company is mainly engaged in the research and development, production and sales of gene sequencing technology platforms, as well as technical promotion services for related products, focusing on helping health and serving the public. Recently, Saina Bio completed the C+ round of financing of over 200 million yuan. This round of financing was led by China State-owned Enterprise Structural Adjustment Fund Phase II (National Research Fund), followed by Wuxi Guolian Guokang Health Industry Investment Center (Limited Partnership) (Wuxi Guolian), and Probe Capital served as the exclusive financial advisor.

This article is reproduced from: https://www.itjuzi.com/investevent/13454707
This site is for inclusion only, and the copyright belongs to the original author.

Leave a Comment

Your email address will not be published.